ProCE Banner Activity

Myelofibrosis: Where We Are and Where We Are Going

Clinical Thought

Read this expert commentary for an overview of where we are now and where we are headed in the management of patients with myelofibrosis.

Released: October 04, 2023

Share

Faculty

Jean-Jacques Kiladjian

Jean-Jacques Kiladjian, MD, PhD

Professor
Department of Clinical Pharmacology
Université de Paris
Professor
Clinical Investigations Center
Saint-Louis Hospital
Paris, France

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from CTI BioPharma Corp., Geron Corporation, GlaxoSmithKline LLC, and Karyopharm Therapeutics Inc.

CTI BioPharma Corp., a Sobi Company

Geron Corporation

GlaxoSmithKline LLC

Karyopharm Therapeutics Inc.

Disclosure

Primary Author

Jean-Jacques Kiladjian, MD, PhD

Professor
Department of Clinical Pharmacology
Université de Paris
Professor
Clinical Investigations Center
Saint-Louis Hospital
Paris, France

Jean-Jacques Kiladijan, MD, PhD: consultant/advisor/speaker: AbbVie, AOP Health, Bristol Myers Squibb, GlaxoSmithKline, Incyte, Novartis, Pharmaessentia.